PepGen to Participate in Upcoming Investor Conferences
04 November 2024 - 2:00PM
Business Wire
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology
company advancing the next generation of oligonucleotide therapies
with the goal of transforming the treatment of severe neuromuscular
and neurological diseases, today announced that management will
participate in the following upcoming investor conferences:
- Guggenheim's Inaugural Healthcare Innovation Conference
(Boston, MA)
- Monday, November 11, 2024 at 1:00 p.m. ET, Fireside Chat
- Stifel 2024 Healthcare Conference (New York, NY)
- Tuesday, November 19, 2024 at 11:30 a.m. ET, Fireside Chat
A webcast of each conference presentation will be available on
the “Events & Presentations” page within the Investors section
of the PepGen website at https://investors.pepgen.com/. Replays of
the webcasts will be available on the PepGen website for 90 days
following the presentation dates.
About PepGen
PepGen is a clinical-stage biotechnology company advancing the
next-generation of oligonucleotide therapies with the goal of
transforming the treatment of severe neuromuscular and neurological
diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform
is founded on over a decade of research and development and
leverages cell-penetrating peptides to improve the uptake and
activity of conjugated oligonucleotide therapeutics. Using these
EDO peptides, we are generating a pipeline of oligonucleotide
therapeutic candidates designed to target the root cause of serious
diseases.
For more information, please visit www.pepgen.com. Follow PepGen
on LinkedIn and X.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241104983620/en/
Investor Contact Dave Borah,
CFA SVP, Investor Relations and Corporate Communications
dborah@pepgen.com
Media Contact Julia Deutsch
Lyra Strategic Advisory Jdeutsch@lyraadvisory.com
PepGen (NASDAQ:PEPG)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
PepGen (NASDAQ:PEPG)
Historical Stock Chart
Von Dez 2023 bis Dez 2024